BioCentury
ARTICLE | Clinical News

RVSV-EBOV: Preliminary Phase II data

April 6, 2015 7:00 AM UTC

Preliminary data from >600 healthy volunteers in the Phase II portion of the double-blind, placebo-controlled, Liberian Phase II/III PREVAIL trial showed that a single injection of cAd-EBOZ or VSV-ZEBOV appears to be safe. The trial is enrolling about 1,500 subjects in the Phase II portion, while the Phase III portion is slated to enroll 27,000 subjects at risk of Ebola virus infection. cAd-EBOZ is a recombinant chimpanzee adenovirus type 3 (cAd3) vector containing segments of genetic material derived from the Zaire strain of Ebola virus from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) and the National Institute of Allergy and Infectious Diseases (NIAID). NIH’s NIAID sponsored the trial. ...